Nuvation Bio Inc. (NUVB)

Market Cap	616.40M
Revenue (ttm)	7.87M
Net Income (ttm)	-567.94M
Shares Out	338.68M
EPS (ttm)	-2.11
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,310,771
Open	1.880
Previous Close	1.870
Day's Range	1.800 - 1.885
52-Week Range	1.705 - 3.970
Beta	1.47
Analysts	Strong Buy
Price Target	8.33 (+357.69%)
Earnings Date	Mar 6, 2025

About NUVB

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its lead product candidate is taletrectinib, an ROS1 inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer; Safusidenib, a novel, oral, potent, brain penetrant, targeted inhibitor of mutant isocitrate dehydrogenase 1 in phase 2 clinical trials; NUV-1511, a drug-drug conjugate for use in chemotherapy agent that suppresses the growth of variou...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2018
• Employees: 220
• Stock Exchange: NYSE
• Ticker Symbol: NUVB
• Website: https://www.nuvationbio.com

Analyst Forecast

According to 6 analysts, the average rating for NUVB stock is "Strong Buy." The 12-month stock price forecast is $8.33, which is an increase of 357.69% from the latest price.

Price Target

$8.33

(357.69% upside)

Analyst Consensus: Strong Buy